MTI Aims To Rebound From Onyx Trial Delays, Focuses European Business
This article was originally published in The Gray Sheet
Executive Summary
Micro Therapeutics, Inc.'s pivotal study of its Onyx liquid embolic system for the treatment of brain aneurysms will remain on target for completion by the third quarter of 2002, with 138 patients on board as predicted, the firm says
You may also be interested in...
Micro Therapeutics, Inc.
Cerebral Aneurysm Multi-Center European Onyx (CAMEO) trial treats 99% (122 of 123) of aneurysms successfully, firm reports Feb. 13. Liquid embolic device hit European market in January, following MTI distribution partnership with ev3 International. In the U.S., MTI completed 30% of total case requirements for two Onyx trials as of year-end 2001, with enrollment completion targeted for the third quarter of 2002 (1"The Gray Sheet" Nov. 5, 2001, p. 26). The Irvine, California company's sales increased 54% in 2001 to $8.8 mil. A net loss of $20.1 mil. compares with a loss of $11.8 mil. in 2000...
Micro Therapeutics, Inc.
Cerebral Aneurysm Multi-Center European Onyx (CAMEO) trial treats 99% (122 of 123) of aneurysms successfully, firm reports Feb. 13. Liquid embolic device hit European market in January, following MTI distribution partnership with ev3 International. In the U.S., MTI completed 30% of total case requirements for two Onyx trials as of year-end 2001, with enrollment completion targeted for the third quarter of 2002 (1"The Gray Sheet" Nov. 5, 2001, p. 26). The Irvine, California company's sales increased 54% in 2001 to $8.8 mil. A net loss of $20.1 mil. compares with a loss of $11.8 mil. in 2000...
Cordis Trufill Embolic System Approval Is Fledgling Neurovascular Unit's First
Cordis Neurovascular plans to launch the Trufill n-butyl cyanoacrylate (n-BCA) liquid embolic system for treatment of cerebral arteriovenous malformations (AVMs) the week of Oct. 2 following FDA approval of the neurovascular glue Sept. 26.